Dr. Christian Devaux
Institut Hospitalo-Universitaire Méditerranée (Marseille, France), Former Director, Health Sciences Section of the CNRS, Member of the High Council, Public Health for Infectious and Emergent Diseases, French Ministry of Health
About this event
- Date and time Mon 27 Jul 2020 from 5:00pm to 6:00pm
- Location Online
- Organised by Medical Genetics
This timely webinar brings together leading world experts in virology, infectious diseases, and human genetics to discuss the latest research on human genetic determinants of COVID-19 susceptibility and severity. This is one of the fastest-paced areas of research undertaken in modern human genetics and medical history.
During this session you will:
- Learn about host genetics that affect COVID-19 incidence and Sars-Cov-2 virulence
- Access latest, cutting edge research on genetic variants ready for clinical practice
- Explore how human genetic variation may be used to chart COVID-19 disease outcome and management
Participants will have first-hand access to the latest findings in promising genetic variants for disease treatment and management. Discovery of human genetics variants would constitute a major leap in our capacity to predict (and protect) populations at risk, as it would help us understand the intricate host genome-virus interactions and how we may interfere with these to slow down or even stop this disease.
This is a must attend webinar for anyone with an interest in the COVID-19 pandemic and current efforts to combat it.
Join in the conversation online using #RSMLive
Follow us on Twitter: @RoySocMed
This webinar is supported by Bristol Myers Squibb in the form of an educational grant. Please note that the scientific programme and content has not been influenced in any way by the sponsor.
The Royal Society of Medicine needs your support
The RSM is offering this webinar at no charge to delegates, in order to help healthcare professionals to easily access COVID-19 related education material & resources during the pandemic. However, we are asking people to support the RSM in these unprecedented times. Now more than ever, as a charity we need your help to continue our work and mission in advancing healthcare through innovation and education. Please consider making a donation for joining this webinar. Thank you for your generosity.
Key speakers
Dr. William Hildebrand
Director, Clinical Human Leukocyte Antigen (HLA) Typing Laboratory and Endowed Professor, University of Oklahoma Health Sciences Center (Oklahoma City, Oklahoma, USA) and President, American Society, Histocompatibility and Immunogenetics
Dr. Mark Daly
Director, The Institute for Molecular Medicine,Finland FIMM, HiLIFE, University of Helsinki, Finland, Chief, Analytic and Translational Genetics Unit (ATGU), Massachusetts General Hospital and Institute Member and Co-Director, Program in Medical and Population Genetics, Broad Institute,Cambridge, MA, USA
Agenda
View the programme
Welcome and introduction
Angiotensin-converting enzyme 2 (ACE2) receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome
Dr Christian Devaux, Institut Hospitalo-Universitaire Méditerranée (Marseille, France), Former Director, Health Sciences Section of the CNRS, Member of the High Council, Public Health for Infectious and Emergent Diseases, French Ministry of Health
Human leukocyte antigen (HLA) typing of COVID-19
Dr William Hildebrand, Director, Clinical Human Leukocyte Antigen (HLA) Typing Laboratory and Endowed Professor, University of Oklahoma Health Sciences Center (Oklahoma City, Oklahoma, USA) and President, American Society, Histocompatibility and Immunogenetics
COVID-19 host genetics initiative: A global effort to identify host genetics contributions to susceptibility and severity
Dr Mark Daly, Director, The Institute for Molecular Medicine,Finland FIMM, HiLIFE, University of Helsinki, Finland,
Chief, Analytic and Translational Genetics Unit (ATGU), Massachusetts General Hospital and Institute Member and Co-Director, Program in Medical and Population Genetics, Broad Institute,Cambridge, MA, USA
Panel discussion
Close of meeting
Sponsors
Location
Online
Disclaimer: All views expressed in this webinar are of the speakers themselves and not of the RSM.
Registration for this webinar will close 2 hours prior to the start time. You will receive the webinar link 2 hours before the meeting. Late registrations will not be accepted.
All webinars will be available for registered delegates 30 days after on Zoom. The link will be sent 24 hours after the webinar takes place.
This webinar will be recorded and stored by the Royal Society of Medicine and may be distributed in future on various internet channels.
More from this series:
COVID-19 and rare diseases: Risks and opportunities posed by the pandemic
This webinar brings together experts from different parts of the rare disease community: primary care, advocacy and medical genetics services. They will discuss the direct impact of the pandemic on rare diseases and the indirect impact of the pandemic on rare disease care provision, in both the short and long-term.
